1National institutes of health, National heart, Lung and Blood Institute. Global strategy for asthma management and prevention. Revised, 2006. http ://www. ginasthma, corn/ Guidelineitem. asp.
2Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med,2004,170:836-844.
3Lundback B, Ronmark E, Lindberg A, et al. Asthma control over 3 years in a real-life study. Respir Med,2009,103:348-355.
5FDA Announces New Safety Controls for Long-Acting Beta Agonists, Medications Used to Treat Asthma. http://www.fda.gov/Drugs/ DrugSafety/ucm187806.
二级参考文献11
1Andersson F, Stahl E, Barnes PJ, et al. Adding formoterol to budesonide in moderate asthma-health economic results from the FACET study. Respir Med, 2001,95:505-512.
2Global initiative for asthma. Global strategy for asthma management and prevention: National Heart, Lung, and Blood Institute. National Institutes of Health: 2006.
3Bateman ED, Boushey HA, Bousquet J, et al. Can guideline- defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med, 2004,170:836-844.
4Lapperre TS, Snoeck-Stroband JB, Gosman MM, ct al. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004, 170:499-504.
5Sont JK, Han J, van Krieken JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax, 1996,51:496-502.
6Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologie outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med, 1999,159 (4 Pt 1) :1043-1051.
7Sont JK. How do we monitor asthma control? Allergy, 1999,54 Suppl 49:68-73.
